Purchase Option

$ 4400
$ 4000
$ 6000

Amyloidosis Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018  

Amyloidosis Pipeline Drugs Assessment

  Overview: Amyloidosis is a rare disease, which occurs due to deposition of amyloid in organs. It is an abnormal protein, produced in the bone marrow and accumulates at any part of the tissue or organ. Amyloidosis may affect different parts of the body in different people. Amyloidosis affects heart, kidney, liver, spleen and nervous system. Amyloidosis is diagnosed with the laboratory tests by identifying the abnormality in the protein in blood and urine. Furthermore, imaging techniques and biopsy may be performed to diagnose the disease and presence of amyloidosis. Treatment is given to relive the symptoms and limit the further production of amyloid. Treatment depends on the type of amyloidosis. Chemotherapeutic agents are used to treat the immunoglobulin light chain amyloidosis and therapies may include autologous blood stem cell transplant. AA amyloidosis is treated by treating underlying condition for example, anti inflammatory drugs for treating rheumatoid arthritis. For Hereditary amyloidosis, liver transplant may be an option.   Segmentation: Amyloidosis pipeline drugs are segmented based on route of administration, trial phase,and company By type, Amyloidosis pipeline drugs are segmented into
  • AL Amyloidosis
  • AA amyloidosis
  • Others
By trial phase, Amyloidosis pipeline drugs are segmented into
  • Pre-clinical phase
  • Phase-I
  • Phase II
  • Phase-III
By company, Amyloidosis pipeline drugs are segmented into
  • GLAXOSMITHKLINE PLC (U.K.)
  • AMGEN INC. (U.S.)
  • ALNYLAM PHARMACEUTICALS, INC., (U.S.)
  • BELLUS HEALTH INC. (CANADA)
  • ARCTURUS THERAPEUTICS (U.S.)
  • JOHNSON & JOHNSON SERVICES INC. (U.S.)
  • IONIS PHARMACEUTICALS, INC. (U.S.)
  Space Analysis:
  • In September 2017 Sanofi and Alnylam Pharmaceuticals reported positive results in late-stage trial of a treatment for hereditary ATTE Amyloidosis patients with polyneuropathy
  Report Description: AmyloidosisPipeline Drugs Assessment report studies the various therapeutics under clinical development for Amyloidosis treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Amyloidosis pipeline drugsdevelopment. This report studies the dynamics of the AmyloidosisPipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Amyloidosis pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.   Key Features of the Report:
  • Provides the information related to universities and research institutes working in the therapeutics development
  • Report comprehensively covers the all active and discontinued studies
  • Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
  • Presents the prominent targets for drug development in each stage of clinical trial
  • Provides the in-depth analysis on each drug candidates in the clinical trial phases
 

Location

GEOGRAPHY

PBI Location Map

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

[urltag url='request-table-of-content']

 

  • GLAXOSMITHKLINE PLC (U.K.)
  • AMGEN INC. (U.S.)
  • ALNYLAM PHARMACEUTICALS, INC., (U.S.)
  • BELLUS HEALTH INC. (CANADA)
  • ARCTURUS THERAPEUTICS (U.S.)
  • JOHNSON & JOHNSON SERVICES INC. (U.S.)
  • IONIS PHARMACEUTICALS, INC. (U.S.)

Adjacent Markets